Skip to main content
. 2020 Jan 7;2020:8736509. doi: 10.1155/2020/8736509

Table 3.

Survival analysis data of the included studies.

Study Marker Cut-off Survival analysis HR 95% CI p value Variables for multivariate analysis
Aggerholm-Pedersen et al. [30] GPS DSSa 3.367 1.993-5.688 <0.001 Age, tumor size, histology, margin, soft tissue extension, comorbidity
OSa 3.387 2.062-5.564 <0.001
Liu et al. [31] GPS OS 2.25 1.222-4.145 0.009 Enneking stage, metastasis, tumor site, CRP, NLR, PLR, LMR
Morhij et al. [32] mGPS CSS 2.03 1.31-3.16 0.002 Tumor size, grade, CRP, ALB, WCC
RFS 1.92 1.31-2.83 0.001 Tumor size, grade, CRP, ALB
Li et al. (1) [34] GPS OS 1.95 1.33-2.87 0.001 Univariate analysis
CAR 0.210 OS 2.62 1.70-4.03 <0.001 Metastasis, tumor site
Li et al. (2) [33] GPS OS 2.27 1.28-4.02 0.006 Univariate analysis
CAR 0.225 OS 2.28 1.23-4.26 0.009 Enneking stage, tumor site
Maretty-Kongstad et al. [35] GPS DSSa 1.731 1.070-2.801 0.026 Age, tumor size, grade, histology, tumor depth, comorbidity
Liang et al. [36] Hs-mGPS OSa 3.162 2.000-4.998 <0.001 Univariate analysis
DFSa 2.232 1.542-3.231 <0.001
CAR 0.1035 OS 2.47 1.47-4.14 0.001 Grade
DFS 1.88 1.22-2.91 0.004 Age, grade
Tsuda et al. [37] Hs-mGPS EFS 1.74 1.01-2.99 0.046 Age, sex, UICC stage, margin, ECOG PS
Jiang et al. [38] GPS OS 0.941 0.117-7.585 0.954 mGPS, age, pathological grade, primary tumor depth
PFS 0.312 0.047-2.664 0.353
mGPS OS 1.660 0.22-12.534 0.623 GPS, age, pathological grade, primary tumor depth
PFS 9.932 1.357-72.716 0.024
Sasaki et al. [39] GPS OS 2.098 1.229-3.388 0.002 Univariate analysis
Aggerholm-Pedersen et al. [40] GPS DSSa 3.195 1.253-8.147 0.015 Age, comorbidity, histology, site of metastasis
Xu et al. [41] CAR 1.5 OS 1.930 1.040-3.579 0.037 Age, Frankel score, resection mode, D-dimer, PLR
DFS 1.687 0.916-3.106 0.093 Age, Frankel score, metastasis, resection mode, D-dimer, PLR

GPS: Glasgow prognostic score; mGPS: modified GPS; Hs-mGPS: high sensitive modified GPS; CAR: C-reactive protein to albumin ratio; OS: overall survival; DSS: disease-specific survival; DFS: disease-free survival; RFS: recurrence-free survival; EFS: event-free survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; CRP: C-reactive protein; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; ALB: albumin; WCC: white cell counts; UICC: Union for International Cancer Control; ECOG PS: Eastern Cooperative Oncology Group performance status.aThese studies reported HRs for GPS 1 and GPS 2 separately. We combined these 2 groups and calculated a combined HR for the overall elevated GPS.